Contact PI/Project LeaderTANG GIRDWOOD, SONYA C Other PIs
Awardee OrganizationCINCINNATI CHILDRENS HOSP MED CTR
Description
Abstract Text
PROJECT SUMMARY/ABSTRACT
During the past 20 years, Congress, the National Institutes of Health (NIH), and the Food and Drug
Administration (FDA) have made it clear that safe drug therapy for children is a high priority. With the rapidly
changing health care and research environments, it has become essential to focus on the training of the next
generation of leaders in Pediatric Clinical Pharmacology who are involved in the design and conduct of hands-
on drug studies in children to augment the translation of new and effective therapies for children. The proposed
Cincinnati Children’s Pediatric Clinical Pharmacology K12 program aims to provide the resources for a diverse
group of junior faculty to become the next leaders in Pediatric Clinical Pharmacology. This includes training in
the principles of Pediatric Clinical Pharmacology to those who may never had previous clinical pharmacology
experience while also facilitating the transition from fellowship to junior faculty to independent investigator for
those who have had previous fellowship training in Pediatric Clinical Pharmacology. The training program we
propose in this application for K12 Scholars will leverage the outstanding research infrastructure that exists within
Cincinnati Children’s Hospital Medical Center and the University of Cincinnati Academic Health Center, the
strong research training activities that we have built within the Cincinnati Children’s Division of Clinical
Pharmacology, and the robust collaborations that our Division has developed with other Clinical Pharmacology
T32 sites and Clinical Pharmacology programs throughout the nation. Through our rigorous training program,
we expect Scholars to achieve the following five core competencies: 1) Foundational Knowledge and Skill in
Pharmacometrics, 2) Foundational Knowledge and Skills in Pharmacogenetics, 3) In-depth Understanding of the
Impact of Developmental Pharmacology Principles on Drug Action and Toxicity, 4) Ability to Conduct Studies in
a Variety of Pediatric Patient Populations, and 5) Collaborative Skills in Interdisciplinary Team Research. The
four pillars of training to achieve these core competencies will be focused on 1) research training, 2) responsible
conduct of research, 3) teaching/research mentorship and 4) leadership and career development through both
experiential learning and didactic courses with knowledge and skills to be attained and expected outcomes in
each of these areas. Intended Scholar outcomes include high impact manuscripts describing research in
Pediatric Clinical Pharmacology, submission of independent K career development awards or R awards, delivery
of lectures and presentations on clinical pharmacology topics in local forums and national conferences,
experience in mentoring trainees locally and nationally, and leadership positions in national committees in
Clinical Pharmacology societies. We intend to have two junior faculty Scholars appointed at any time with the
anticipated appointments being 2 to 3 years, depending on external grant funding. This program will expand the
critically small pool of Pediatric Clinical Pharmacology investigators who will advance personalized therapeutics
in pediatrics to improve the health outcomes of children.
Public Health Relevance Statement
NARRATIVE
The Cincinnati Children’s K12 Pediatric Clinical Pharmacology Program will provide the essential resources to
expand the critically small pool of pediatric clinical pharmacologists by training a diverse group of junior faculty
to become the next generation of independent investigators in the field of Pediatric Clinical Pharmacology. The
K12 Scholars will be equipped to lead the development of innovative clinical pharmacology approaches that
transform the use of medications in pediatrics. The program will further advance the mission to implement
personalized pediatric therapeutics to improve clinical outcomes of children.
NIH Spending Category
No NIH Spending Category available.
Project Terms
Active LearningAppointmentAreaAwardChildChildhoodClinical PharmacologyCollaborationsCompetenceCongressesDevelopmentDrug toxicityEducational process of instructingEnvironmentFacultyFellowshipFundingGrantHealthHealthcareK-Series Research Career ProgramsKnowledgeLeadershipManuscriptsMedical centerMentored Clinical Scientist Development ProgramMentorsMentorshipOutcomePediatric HospitalsPediatricsPharmaceutical PreparationsPharmacogeneticsPharmacologyPharmacotherapyPositioning AttributeResearchResearch InfrastructureResearch PersonnelResearch TrainingResourcesSiteSocietiesTimeTrainingTraining ActivityTraining ProgramsTranslationsUnited States Food and Drug AdministrationUnited States National Institutes of HealthUniversitiescareer developmentdesigndrug actioneffective therapyexperienceimprovedleadership developmentlecturesnext generationnovel therapeuticspatient populationpediatric patientspersonalized therapeuticpharmacometricsprogramsresponsible research conductskillssymposium
Eunice Kennedy Shriver National Institute of Child Health and Human Development
CFDA Code
865
DUNS Number
071284913
UEI
JZD1HLM2ZU83
Project Start Date
01-August-2023
Project End Date
31-July-2028
Budget Start Date
01-August-2024
Budget End Date
31-July-2025
Project Funding Information for 2024
Total Funding
$297,000
Direct Costs
$275,000
Indirect Costs
$22,000
Year
Funding IC
FY Total Cost by IC
2024
Eunice Kennedy Shriver National Institute of Child Health and Human Development
$297,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5K12HD113190-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5K12HD113190-02
Patents
No Patents information available for 5K12HD113190-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5K12HD113190-02
Clinical Studies
No Clinical Studies information available for 5K12HD113190-02
News and More
Related News Releases
No news release information available for 5K12HD113190-02
History
No Historical information available for 5K12HD113190-02
Similar Projects
No Similar Projects information available for 5K12HD113190-02